{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:34:58Z","timestamp":1790357698986,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,16]]},"DOI":"10.7759\/cureus.86113","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T09:17:33Z","timestamp":1750065453000},"source":"Crossref","is-referenced-by-count":4,"title":["Recurrence of Intraocular Inflammation Following an Aflibercept 8-mg Injection in Eyes With a History of Intraocular Inflammation From Faricimab: A Case Report"],"prefix":"10.7759","author":[{"given":"Shiori","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Sakurada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Kotoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S489114","article-title":"Outcomes of anti-VEGF therapy in eyes with diabetic macular edema, vein occlusion-related macular edema, and neovascular age-related macular degeneration: a systematic review","volume":"18","author":"Aldokhail LS","year":"2024","unstructured":"Aldokhail LS, Alhadlaq AM, Alaradi LM, Alaradi LM, AlShaikh FY. Outcomes of anti-VEGF therapy in eyes with diabetic macular edema, vein occlusion-related macular edema, and neovascular age-related macular degeneration: a systematic review. Clin Ophthalmol. 2024, 18:3837-51. 10.2147\/OPTH.S489114","journal-title":"Clin Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld PJ","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006, 355:1419-31. 10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier JS","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, et al.. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012, 119:2537-48. 10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel PU","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, et al.. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020, 127:72-84. 10.1016\/j.ophtha.2019.04.017","journal-title":"Ophthalmology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier JS","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al.. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022, 399:729-40. 10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta P","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, et al.. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024, 403:1141-52. 10.1016\/S0140-6736(24)00063-1","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-022-05611-y","article-title":"Sub-Tenon's capsule triamcinolone acetonide injection to prevent brolucizumab-associated intraocular inflammation","volume":"260","author":"Hikichi T","year":"2022","unstructured":"Hikichi T. Sub-Tenon's capsule triamcinolone acetonide injection to prevent brolucizumab-associated intraocular inflammation. Graefes Arch Clin Exp Ophthalmol. 2022, 260:2529-35. 10.1007\/s00417-022-05611-y","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027580","article-title":"The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation","volume":"100","author":"Shigemoto Y","year":"2021","unstructured":"Shigemoto Y, Sakurada Y, Fukuda Y, Matsubara M, Parikh R, Kashiwagi K. The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation. Medicine (Baltimore). 2021, 100:e27580. 10.1097\/MD.0000000000027580","journal-title":"Medicine (Baltimore)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2020.09.020","article-title":"Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment","volume":"5","author":"Baumal CR","year":"2021","unstructured":"Baumal CR, Bodaghi B, Singer M, et al.. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmol Retina. 2021, 5:519-27. 10.1016\/j.oret.2020.09.020","journal-title":"Ophthalmol Retina"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","volume":"127","author":"Baumal CR","year":"2020","unstructured":"Baumal CR, Spaide RF, Vajzovic L, et al.. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020, 127:1345-59. 10.1016\/j.ophtha.2020.04.017","journal-title":"Ophthalmology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000004009","article-title":"Incidence and risk factors of intraocular inflammation after brolucizumab treatment in Japan: a multicenter age-related macular degeneration study","volume":"44","author":"Inoda S","year":"2024","unstructured":"Inoda S, Takahashi H, Maruyama-Inoue M, et al.. Incidence and risk factors of intraocular inflammation after brolucizumab treatment in Japan: a multicenter age-related macular degeneration study. Retina. 2024, 44:714-22. 10.1097\/IAE.0000000000004009","journal-title":"Retina"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-023-00999-4","article-title":"Comparison of one-year outcomes between as-needed brolucizumab and aflibercept for polypoidal choroidal vasculopathy","volume":"67","author":"Fukuda Y","year":"2023","unstructured":"Fukuda Y, Sakurada Y, Matsubara M, Kotoda Y, Kasai Y, Sugiyama A, Kashiwagi K. Comparison of one-year outcomes between as-needed brolucizumab and aflibercept for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2023, 67:402-9. 10.1007\/s10384-023-00999-4","journal-title":"Jpn J Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05136-w","article-title":"Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study","volume":"259","author":"Maruko I","year":"2021","unstructured":"Maruko I, Okada AA, Iida T, et al.. Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study. Graefes Arch Clin Exp Ophthalmol. 2021, 259:2857-9. 10.1007\/s00417-021-05136-w","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-025-06736-6","article-title":"Vitritis following intravitreal faricimab: a retrospective monocentric analysis","volume":"263","author":"Bourdin A","year":"2025","unstructured":"Bourdin A, Cohen SY, Nghiem-Buffet S, Smadja J, Paques M, Fajnkuchen F, Mrejen S. Vitritis following intravitreal faricimab: a retrospective monocentric analysis. Graefes Arch Clin Exp Ophthalmol. 2025, 263:965-72. 10.1007\/s00417-025-06736-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ph18030438","article-title":"Short-term outcomes of three consecutive monthly loading administrations of aflibercept 8 mg for treatment-na\u00efve exudative age-related macular degeneration","volume":"18","author":"Hosoda S","year":"2025","unstructured":"Hosoda S, Sakurada Y, Fukuda Y, Kotoda Y, Kikushima W, Kashiwagi K. Short-term outcomes of three consecutive monthly loading administrations of aflibercept 8 mg for treatment-na\u00efve exudative age-related macular degeneration. Pharmaceuticals (Basel). 2025, 18:30438. 10.3390\/ph18030438","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-024-01107-w","article-title":"Retinal vasculitis after intravitreal aflibercept 8\u00a0mg for neovascular age-related macular degeneration","volume":"68","author":"Matsumoto H","year":"2024","unstructured":"Matsumoto H, Hoshino J, Numaga S, Mimura K, Asatori Y, Akiyama H. Retinal vasculitis after intravitreal aflibercept 8\u00a0mg for neovascular age-related macular degeneration. Jpn J Ophthalmol. 2024, 68:531-7. 10.1007\/s10384-024-01107-w","journal-title":"Jpn J Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-024-03788-w","article-title":"Aflibercept high-dose (8mg) related intraocular inflammation (IOI) - a case series","volume":"24","author":"Hoffmann L","year":"2024","unstructured":"Hoffmann L, Michels S, Eandi C, Karam MA, Figueiredo EC, Hatz K. Aflibercept high-dose (8mg) related intraocular inflammation (IOI) - a case series. BMC Ophthalmol. 2024, 24:520. 10.1186\/s12886-024-03788-w","journal-title":"BMC Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.0530","article-title":"Severe intraocular inflammation following intravitreal faricimab","volume":"142","author":"Thangamathesvaran L","year":"2024","unstructured":"Thangamathesvaran L, Kong J, Bressler SB, et al.. Severe intraocular inflammation following intravitreal faricimab. JAMA Ophthalmol. 2024, 142:365-70. 10.1001\/jamaophthalmol.2024.0530","journal-title":"JAMA Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/363063-recurrence-of-intraocular-inflammation-following-an-aflibercept-8-mg-injection-in-eyes-with-a-history-of-intraocular-inflammation-from-faricimab-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T09:17:33Z","timestamp":1750065453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/363063-recurrence-of-intraocular-inflammation-following-an-aflibercept-8-mg-injection-in-eyes-with-a-history-of-intraocular-inflammation-from-faricimab-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.86113","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,16]]}}}